{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:47:51Z","timestamp":1786650471640,"version":"build-2736575974"},"reference-count":59,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Indian J Pharmacol"],"published-print":{"date-parts":[[2013]]},"DOI":"10.4103\/0253-7613.121266","type":"journal-article","created":{"date-parts":[[2013,11,14]],"date-time":"2013-11-14T04:12:50Z","timestamp":1384402370000},"page":"547","source":"Crossref","is-referenced-by-count":22,"title":["Zonisamide: A review of the clinical and experimental evidence for its use in Parkinson\u2032s disease"],"prefix":"10.4103","volume":"45","author":[{"given":"NeetaD","family":"Grover","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"RamachandraP","family":"Limaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DilipV","family":"Gokhale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"TatyasahebR","family":"Patil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/0253-7613.121266-1","unstructured":"Fahn S, Przedbroski S. Parkinson\u2032s Disease. In: Rowland LP, Pedley TA, editors. Chapter in Merritt\u2032s Neurology. 12 th ed. Wolters Kluwer-Lippincott Williams and Wilkins,Philadelphia; 2010. p. 751-69."},{"key":"key-10.4103\/0253-7613.121266-2","unstructured":"Standaert DG, Roberson ED. Treatment of central nervous system degenerative disorders. In: Brunton LL, editor. Chapter in Goodman and Gilman\u2032s The Pharmacological Basis of Therapeutics. 12 th ed. McGraw Hill, NewYork; 2011. p. 609-28."},{"key":"key-10.4103\/0253-7613.121266-3","first-page":"1083","volume-title":"Treatment options in modern management of PD","author":"Schapira","year":"2007","journal-title":"Arch Neurol"},{"key":"key-10.4103\/0253-7613.121266-4","first-page":"S49","volume-title":"Parkinson\u2032s Disease- Part 2: Treatment of motor symptoms","author":"Weintraub","year":"2008","journal-title":"Am J Manag Care"},{"key":"key-10.4103\/0253-7613.121266-5","first-page":"223","volume-title":"Antiepileptic drugs: Pharmacological mechanisms and clinical efficacy with consideration of promising developmental stage compounds","author":"Rogawski","year":"1990","journal-title":"Pharmacol Rev"},{"key":"key-10.4103\/0253-7613.121266-6","first-page":"21","volume-title":"Zonisamide blocks T-type calcium channel in cultured neurons of rat cerebral cortex","author":"Suzuki","year":"1992","journal-title":"Epilepsy Res"},{"key":"key-10.4103\/0253-7613.121266-7","first-page":"1","volume-title":"Effect of zonisamide on molecular regulation of glutamate and GABA transporter proteins during epileptogenesis in rats with hippocampal seizures","author":"Ueda","year":"2003","journal-title":"Brain Res Mol Brain Res"},{"key":"key-10.4103\/0253-7613.121266-8","first-page":"1277","volume-title":"Interaction between Ca2+, K+, carbamazepine and zonisamide on hippocampal extracellular glutamate monitored with a microdialysis electrode","author":"Okada","year":"1998","journal-title":"Br J Pharmacol"},{"key":"key-10.4103\/0253-7613.121266-9","first-page":"193","volume-title":"Effects of zonisamide on dopaminergic system","author":"Okada","year":"1995","journal-title":"Epilepsy Res"},{"key":"key-10.4103\/0253-7613.121266-10","first-page":"187","volume-title":"Biphasic effects of zonisamide on serotonergic system in rat hippocampus","author":"Okada","year":"1999","journal-title":"Epilepsy Res"},{"key":"key-10.4103\/0253-7613.121266-11","first-page":"173","volume-title":"effects of zonisamide on K+ and Ca2+ evoked release of monoamine as well as K+ evoked intracellular Ca2+ mobilization in rat hippocampus","author":"Kawata","year":"1999","journal-title":"Epilepsy Res"},{"key":"key-10.4103\/0253-7613.121266-12","unstructured":"Pharmaceuticals and Medical Devices Agency Japan. Tablet Trerief 25 mg, approved by PMDA, Japan on Jan 21st 2009. Accessed from the official website of PMDA. Available from: http:\/\/www.pmda.go.jp\/english\/service\/pdf\/list\/NewdrugsFY2008.pdf [Last accessed in 2012 Jun]."},{"key":"key-10.4103\/0253-7613.121266-13","first-page":"738","volume-title":"The unified Parkinson\u2032s disease rating scale: status and recommendations","author":"Movement","year":"2003","journal-title":"Mov Disord"},{"key":"key-10.4103\/0253-7613.121266-14","first-page":"1020","volume-title":"Movement Disorder Society Task Force Report on the Hoehn and Yahr Staging Scale: Status and Recommendations","author":"Goetz","year":"2004","journal-title":"Mov Disord"},{"key":"key-10.4103\/0253-7613.121266-15","first-page":"397","volume-title":"Zonisamide has beneficial effects on Parkinson\u2032s disease patients","author":"Murata","year":"2001","journal-title":"Neurosci Res"},{"key":"key-10.4103\/0253-7613.121266-16","first-page":"685","volume-title":"Effect of zonisamide on resting tremor resistant to antiparkinsonian medication","author":"Nakanishi","year":"2003","journal-title":"No To Shinkei"},{"key":"key-10.4103\/0253-7613.121266-17","first-page":"P555","volume-title":"Randomized, double-blind study of zonisamide with placebo in advanced Parkinson\u2032s disease","author":"Murata","year":"2004","journal-title":"Mov Disord"},{"key":"key-10.4103\/0253-7613.121266-18","first-page":"45","volume-title":"Zonisamide improves motor function in Parkinson\u2032s disease: A randomized, double- blind study","author":"Murata","year":"2007","journal-title":"Neurology"},{"key":"key-10.4103\/0253-7613.121266-19","first-page":"1682","volume-title":"Zonisamide in managing impulse control disorders in Parkinson\u2032s disease","author":"Bermejo","year":"2010","journal-title":"J Neurol"},{"key":"key-10.4103\/0253-7613.121266-20","first-page":"S93","volume-title":"Dopamine and impulse control disorders in Parkinson\u2032s disease","author":"Weintraub","year":"2008","journal-title":"Ann Neurol"},{"key":"key-10.4103\/0253-7613.121266-21","first-page":"589","volume-title":"Impulse control disorders in Parkinson\u2032s disease: A cross-sectional study of 3090 patients","author":"Weintraub","year":"2010","journal-title":"Arch Neurol"},{"key":"key-10.4103\/0253-7613.121266-22","first-page":"385","volume-title":"Fifty years of the Barratt Impulsiveness Scale: An update and review","author":"Stanford","year":"2009","journal-title":"Pers Individ Dif"},{"key":"key-10.4103\/0253-7613.121266-23","first-page":"2","volume-title":"The movement disorder society evidence based medicine review update: Treatments for the motor symptoms of Parkinson\u2032s disease","author":"Fox","year":"2011","journal-title":"Mov Disord"},{"key":"key-10.4103\/0253-7613.121266-24","first-page":"S335","volume-title":"The Pathogenesis of Cell Death in Parkinson\u2032s Disease-2007","author":"Olanow","year":"2007","journal-title":"Mov Disord"},{"key":"key-10.4103\/0253-7613.121266-25","first-page":"845618","volume-title":"Classic and new animal models of Parkinson\u2032s disease","author":"Blesa","year":"2012","journal-title":"J Biomed Biotechnol"},{"key":"key-10.4103\/0253-7613.121266-26","first-page":"951709","volume-title":"Toxin-induced and genetic models of Parkinson\u2032s disease","author":"Hisahara","year":"2010","journal-title":"Parkinsons Dis"},{"key":"key-10.4103\/0253-7613.121266-27","first-page":"658083","volume-title":"Limitations of animal models of Parkinson\u2032s disease","author":"Potashkin","year":"2010","journal-title":"Parkinsons Dis"},{"key":"key-10.4103\/0253-7613.121266-28","first-page":"19","volume-title":"Brain slices as models for neurodegenerative disease and screening platforms to identify novel therapeutics","author":"Cho","year":"2007","journal-title":"Curr Neuropharmacol"},{"key":"key-10.4103\/0253-7613.121266-29","first-page":"1082","volume-title":"Tyrosinase-expressing neuronal cell line as in vitro model of Parkinson\u2032s disease","author":"Hasegawa","year":"2010","journal-title":"Int J Mol Sci"},{"key":"key-10.4103\/0253-7613.121266-30","first-page":"7006","volume-title":"An in vitro model of Parkinson\u2032s disease: Linking mitochondrial Iimpairment to altered \u00e1 synuclein metabolism and oxidative damage","author":"Sherer","year":"2002","journal-title":"J Neurosci"},{"key":"key-10.4103\/0253-7613.121266-31","first-page":"e15222","volume-title":"Reliability in the identification of midbrain dopamine neurons","author":"Margolis","year":"2010","journal-title":"PLoS One"},{"key":"key-10.4103\/0253-7613.121266-32","first-page":"221","volume-title":"Quinone formation as dopaminergic neuron -specific oxidative stress in the pathogenesis of sporadic Parkinson\u2032s disease and neurotoxin- induced Parkinsonism","author":"Asanuma","year":"2004","journal-title":"Acta Med Okayama"},{"key":"key-10.4103\/0253-7613.121266-33","first-page":"1","volume-title":"Mitochondrial contribution to Parkinson\u2032s disease","author":"Schapira","year":"2011","journal-title":"Parkinsons Dis"},{"key":"key-10.4103\/0253-7613.121266-34","first-page":"106","volume-title":"Preventing effects of a novel anti-parkinsonian agent zonisamide on dopamine quinone formation","author":"Asanuma","year":"2008","journal-title":"Neurosci Res"},{"key":"key-10.4103\/0253-7613.121266-35","first-page":"239","volume-title":"Neuroprotective effects of zonisamide target astrocyte","author":"Asanuma","year":"2010","journal-title":"Ann Neurol"},{"key":"key-10.4103\/0253-7613.121266-36","first-page":"170","volume-title":"Zonosamide induced long lasting recovery of dopaminergic neurons form MPTP-toxicity","author":"Choudhury","year":"2011","journal-title":"Brain Res"},{"key":"key-10.4103\/0253-7613.121266-37","first-page":"217","volume-title":"Electrophysiological actions of zonisamide on striatal neurons: selective neuroprotection against complex I mitochondrial dysfunction","author":"Costa","year":"2010","journal-title":"Exp Neurol"},{"key":"key-10.4103\/0253-7613.121266-38","first-page":"88","volume-title":"Zonisamide reduces cell death in SH-SY5Y cells via an anti-apoptotic effect and by upregulating MnSOD","author":"Kawajiri","year":"2010","journal-title":"Neurosci Lett"},{"key":"key-10.4103\/0253-7613.121266-39","first-page":"72","volume-title":"Zonisamide up-regulated the mRNAs encoding astrocytic anti-oxidative and neurotrophic factors","author":"Choudhury","year":"2012","journal-title":"Eur J Pharmacol"},{"key":"key-10.4103\/0253-7613.121266-40","first-page":"168","volume-title":"Microglial activation and dopaminergic terminal loss in early Parkinson\u2032s disease","author":"Ouchi","year":"2005","journal-title":"Ann Neurol"},{"key":"key-10.4103\/0253-7613.121266-41","first-page":"6","volume-title":"Glia: Initiators and progressors of pathology in Parkinson\u2032s disease","author":"Halliday","year":"2011","journal-title":"Mov Disord"},{"key":"key-10.4103\/0253-7613.121266-42","first-page":"305","volume-title":"Therapeutic effect of a novel anti-parkinsonian agent zonisamide against MPTP(1-methyl-4-phenyl-1,2,3,6-terahydropyridine) neurotoxicity in mice","author":"Yokoyama","year":"2010","journal-title":"Metab Brain Dis"},{"key":"key-10.4103\/0253-7613.121266-43","first-page":"211","volume-title":"A novel anti-Parkinsonian agent, zonisamide, attenuates MPTP- induced neurotoxicity in mice","author":"Yano","year":"2009","journal-title":"J Mol Neurosci"},{"key":"key-10.4103\/0253-7613.121266-44","first-page":"713","volume-title":"Novel dopamine releasing response of an anti-convulsant agent with possible anti-Parkinson\u2032s activity","author":"Gluck","year":"2004","journal-title":"J Neural Transm"},{"key":"key-10.4103\/0253-7613.121266-45","first-page":"S311","volume-title":"Zonisamide increased metabolism of dopamine neurons in MPTP-treated C57BL\/6 and common marmosets","author":"Kubo","year":"2008","journal-title":"Mov Disord"},{"key":"key-10.4103\/0253-7613.121266-46","first-page":"64","volume-title":"Zonisamide increases dopamine turnover in the striatum of mice and common marmosets treated with MPTP","author":"Yabe","year":"2009","journal-title":"J Pharmacol Sci"},{"key":"key-10.4103\/0253-7613.121266-47","first-page":"322","volume-title":"Zonisamide enhances delta receptor-associated neurotransmitter release in striato-pallidal pathway","author":"Yamamura","year":"2009","journal-title":"Neuropharmacology"},{"key":"key-10.4103\/0253-7613.121266-48","first-page":"507","volume-title":"Determination of effects of antiepileptic drugs on SNAREs-mediated hippocampal monoamine release using in vivo microdialysis","author":"Murakami","year":"2001","journal-title":"Br J Pharmacol"},{"key":"key-10.4103\/0253-7613.121266-49","first-page":"329","volume-title":"The antiepileptic drug zonisamide inhibits MAO-B and attenuates MPTP toxicity in mice: Clinical relevance","author":"Sonsalla","year":"2010","journal-title":"Exp Neurol"},{"key":"key-10.4103\/0253-7613.121266-50","first-page":"909","volume-title":"Interactions of monoamine oxidases with the antiepileptic drug zonisamide: Specificity of inhibition and structure of the human monoamine oxidase B complex","author":"Binda","year":"2011","journal-title":"J Med Chem"},{"key":"key-10.4103\/0253-7613.121266-51","first-page":"S63","volume-title":"A molecular basis for the increased vulnerability of substantia nigra dopamine neurons in aging and Parkinson\u2032s disease","author":"Chan","year":"2010","journal-title":"Mov Disord"},{"key":"key-10.4103\/0253-7613.121266-52","first-page":"221","volume-title":"The role of calcium and mitochondrial oxidant stress in the loss of substantia nigra pars compacta dopaminergic neurons in Parkinson\u2032s disease","author":"Surmeier","year":"2011","journal-title":"Neuroscience"},{"key":"key-10.4103\/0253-7613.121266-53","unstructured":"Phase II safety and tolerability of isradipine (a potential neuroprotective agent) in patients with Parkinson\u2032s disease-Stage II. Clinical Trials Identifier NCT00753636. Available from: http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00753636?term = isradipineandrank = 1 [Last accessed on 2012 Aug 06]."},{"key":"key-10.4103\/0253-7613.121266-54","first-page":"903","volume-title":"Role of voltage gated L-type Ca2+ channel isoforms for brain function","author":"Striessnig","year":"2006","journal-title":"Biochem Soc Trans"},{"key":"key-10.4103\/0253-7613.121266-55","first-page":"527","volume-title":"HRD1 levels increased by zonisamide prevented cell death and caspase-3 activation caused by endoplasmic reticulum stress in SH-SY5Y cells","author":"Omura","year":"2012","journal-title":"J Mol Neurosci"},{"key":"key-10.4103\/0253-7613.121266-56","first-page":"205","volume-title":"Zonisamide attenuates MPP+-induced oxidative toxicity through modulation of Ca2+ signaling and caspase-3 activity in neuronal PC12 cells","author":"Y\u00fcrekli","year":"2013","journal-title":"Cell Mol Neurobiol"},{"key":"key-10.4103\/0253-7613.121266-57","first-page":"719","volume-title":"Epidemiology of Parkinson\u2032s disease and movement disorders in India: problems and possibilities","author":"Muthane","year":"2007","journal-title":"JAPI"},{"key":"key-10.4103\/0253-7613.121266-58","first-page":"258","volume-title":"Experiences of Parkinson\u2032s disease in India","author":"Behari","year":"2002","journal-title":"Lancet Neurol"},{"key":"key-10.4103\/0253-7613.121266-59","first-page":"687","volume-title":"Novel therapeutic effects of the anti-convulsant, zonisamide, on Parkinson\u2032s disease","author":"Murata","year":"2004","journal-title":"Curr Pharm Des"}],"container-title":["Indian Journal of Pharmacology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:19:03Z","timestamp":1786648743000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/0253-7613.121266"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013]]},"references-count":59,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013]]}},"alternative-id":["121266"],"URL":"https:\/\/doi.org\/10.4103\/0253-7613.121266","relation":{},"ISSN":["0253-7613"],"issn-type":[{"value":"0253-7613","type":"print"}],"subject":[],"published":{"date-parts":[[2013]]}}}